SCHEMBL2272151

SCHEMBL2272151

Cc1cc(N2CCC(=O)CC2)ncn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.39
CYP2C19 P33261 1/20 0.38
KMO O15229 1/20 0.37
CYP1A2 P05177 5/20 0.37
PIK3CA P42336 1/20 0.36
MTOR P42345 1/20 0.36
HRH4 Q9H3N8 3/20 0.36
ALDH1A1 P00352 3/20 0.35
TSHR P16473 2/20 0.35
CYP2C9 P11712 1/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
RECQL P46063 1/20 0.35
RAB9A P51151 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
KCNQ2 O43526 1/20 0.35
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15114915 0.81 SMN1; SMN2 (0.46) CYP2C19CYP1A2HRH4ALDH1A1TSHR
SCHEMBL11981553 0.81 SMN1; SMN2 (0.50) CYP2C19HRH4ALDH1A1TSHRMAPK1
SCHEMBL28217397 0.79 SMN1; SMN2 (0.53) CYP2C19CYP1A2HRH4ALDH1A1TSHR
SCHEMBL6894413 0.79 OGA (0.44) CYP17A1CYP2C19KMOCYP1A2HRH4
SCHEMBL7497076 0.78 CYP2C19 (0.65) CYP17A1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL12497703 0.78 HRH4 (0.57) CYP2C19CYP1A2HRH4ALDH1A1TSHR
SCHEMBL207751 0.78 CYP1A2 (0.41) CYP2C19KMOCYP1A2HRH4ALDH1A1
SCHEMBL14872341 0.77 LRRK2 (0.41) CYP2C19KMOCYP1A2HRH4ALDH1A1
SCHEMBL10272311 0.76 CYP2C19 (0.63) CYP2C19KMOCYP1A2HRH4ALDH1A1
SCHEMBL14538234 0.76 CYP1A2 (0.57) CYP2C19CYP1A2HRH4ALDH1A1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2536710-B1 PIPERIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2016-07-13 EP disclosed
US-8486967-B2 Heteroaryl substituted piperidines HOFFMANN-LA ROCHE INC. (US) 2013-07-16 US disclosed
CN-103025724-A Piperidine derivatives HOFFMANN LA ROCHE 2013-04-03 CN disclosed
EP-2536710-A2 PIPERIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-12-26 EP disclosed
WO-2011101304-A2 PIPERIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-08-25 WO disclosed
US-20110201605-A1 HETEROARYL SUBSTITUTED PIPERIDINES HOFFMANN-LA ROCHE, INC. 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201605-A1 HETEROARYL SUBSTITUTED PIPERIDINES APP, HPGDS, PSEN1 CYP17A1 3103/4885CYP2C19 2679/4885KMO 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.